Dasatinib treatment results in a strong inhibition of GPVI receptor agonist-induced platelet procoagulant activity in vitro and in CML patients, and this effect may contribute to hemorrhagic consequences of dasatinib treated patients with endothelial disruption or damage when GPVI activating agonists like subendothelial collagen is exposed. This evidence concerns the gene GP6 and chronic myelogenous leukemia, BCR-ABL1 positive.